| Ticker: BGMR | 6660 Doubletree Avenue | |
| Exchange: NASDAQ-Small Cap Market | Columbus, Ohio 43229 | |
| Industry: Manufacturing | (614) 848-8380 |
| Type of Shares: | Common Shares | Filing Date: | 4/19/96 | |
| U.S. Shares: | 1,400,000 | Offer Date: | 6/19/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $7.00 - $9.00 | |
| Primary Shares: | 1,400,000 | Offer Price: | $7.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.68 | |
| Offering Amount: | $11,200,000 | Selling: | $0.40 | |
| Expenses: | $1,150,000 | Reallowance: | $0.10 | |
| Shares Out After: | 3,775,000 |
| Manager | Tier | Phone |
| L.T. Lawrence & Company | Lead Manager | (212) 361-6000 |
| Fechtor, Detwiler & Co. | Co-manager | (617) 451-0100 |
| Auditor: Eisner, Richard A. | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $5.60 | $1.90 | $1.19 | Assets: | $19.30 |
| Net Income: | -$0.10 | $0.05 | $0.09 | Liabilities: | $15.40 |
| EPS: | -$0.07 | $0.02 | $0.23 | Equity: | $3.90 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company manufactures intravenous infusion solutions, markets raw materials used to manufacture medications for the treatment of prostate enlargement, as well as markets other products. Over the next 24 months, the Company intends to manufacture, in its state of the art facilities in Switzerland, and market generic oncological drugs. In addition, the Company is in the process of preparing to market certain licensed proprietary oncological and biotechnological products. The Company markets IV Solutions through its own sales force to health care providers and third-party payors and markets Prostate Materials, mercaptopurine and calcium leucovorin to pharmaceutical companies. The Company does not intend to market its other products directly to the public. For the year ended December 31,1995, on a pro forma basis after giving effect to the Bioren Acquisition as if the transaction had occurred on January 1, 1995, the Company's sales of IV Solutions were approximately $6.5 million, sales of medical products, including Prostate Materials, were approximately $1.4 million, and sales of generic oncological products were approximately $670,000. |
| Use of Proceeds |
| The proceeds from the offering will be used to acquire, test and/or manufacture oncological biotechnological products, to repay debt and for general corporate purposes, including working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.